<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01866566</url>
  </required_header>
  <id_info>
    <org_study_id>BJCDPC-9</org_study_id>
    <nct_id>NCT01866566</nct_id>
  </id_info>
  <brief_title>The Safety and Immunogenicity Research of Live Attenuated Varicella Vaccine After the 2 Doses Vaccination</brief_title>
  <official_title>Phase 4 Study of Live Attenuated Varicella Vaccine After the 2 Doses Vaccination</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Center for Disease Control and Prevention</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Center for Disease Control and Prevention</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Through evaluating the immunogenicity and safety for Varicella vaccine two doses immune
      procedure we could supply scientific and practical evidence for this two doses immune
      procedure promotion and management.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Healthy participants aged 1 to 12 years old who had never received Varicella Vaccine are
      divided into three age groups, 1 to 3 years old group, 4 to 6 years old group and 7-12 years
      old group. In each age group, participants are randomly divided into experiment group and
      control groups.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">January 2016</completion_date>
  <primary_completion_date type="Anticipated">January 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Antibody titer after 2 doses lived attenuated varicella vaccination</measure>
    <time_frame>1 year</time_frame>
    <description>Serums are collected from all participants before and 42 days after the first vaccination, and also 42 days after the second vaccination. The antibody titer to Varicella was detected through FAMA test.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants who have adverse reaction</measure>
    <time_frame>1 year</time_frame>
    <description>The safety is evaluated by systemic and local reaction after each vaccination.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of participants who catch chickenpox</measure>
    <time_frame>3 years</time_frame>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">1800</enrollment>
  <condition>Varicella</condition>
  <arm_group>
    <arm_group_label>HBV-3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>one dose HBV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HBV-6</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>one dose HBV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>varicella-3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 doses varicella vaccine either BCHT or Kengen and 3 month of the interval time</description>
  </arm_group>
  <arm_group>
    <arm_group_label>varicella-6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 doses varicella vaccine either BCHT or Kengen and 6 month of the interval time</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HBV-3</intervention_name>
    <description>Give a single 0.5 mL HBV and get blood samples at 0,1.5,4.5 month</description>
    <arm_group_label>HBV-3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HBV-6</intervention_name>
    <description>Give a single 0.5 mL HBV and get blood samples at 0,1.5,7.5 month</description>
    <arm_group_label>HBV-6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>varicella-3</intervention_name>
    <description>Give 2 doses varicella vaccine (a single 0.5 mL) and get blood samples at 0,1.5,4.5 month</description>
    <arm_group_label>varicella-3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>varicella-6</intervention_name>
    <description>Give 2 doses varicella vaccine (a single 0.5 mL) and get blood samples at 0,1.5,7.5 month</description>
    <arm_group_label>varicella-6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        -Participants from Shanxi province are between 1-12 years old are in good healthy
        determined through medical inquiry, physical examination, clinical judgment of the
        investor.

        Exclusion Criteria:

          1. Having a fever (axillary temperature＞37.0℃) before enrollment;

          2. Having a disease history of seizures, brain disease and the vaccination history of
             allergies and convulsions;

          3. Antibiotics allergy;

          4. Having a problem of intramuscular injection because thrombocytopenia or other blood
             coagulation disorder;

          5. Having immunodeficiency or under immunosuppression therapy, radiation therapy;

          6. Having respiratory diseases, acute infection, chronic disease and HIV infection;

          7. Having systemic skin rash, skin tinea, herpes;

          8. Chronic liver and kidney disease;

          9. Heart disease, and severe hypertension;

         10. Have received whole blood, plasma or immunoglobulin therapy 3 months before
             enrollment;

         11. Have received other live attenuated vaccine vaccination in 30 days before enrollment;

         12. Had been infected with Varicella virus and displayed symptom;

         13. Have received one or two dose of Varicella vaccine before enrollment;

         14. Congenital malformations, growth disorders such as Down's syndrome, diabetes, sickle
             cell anemia and nervous disorders

         15. Guillain-barre syndrome

         16. Thyroid resection history or thyroid disease treatment in the past 12 months;

         17. Asthma

         18. Have participated in other clinical research;

         19. Have serious adverse reactions after vaccination, such as allergies, hives, breathing
             difficulties, angioneurotic edema.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nianmin Shi</last_name>
    <role>Study Chair</role>
    <affiliation>Beijing Chaoyang District Centers for Disease Control and Prevention</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nianmin Shi</last_name>
    <phone>86-010-67773550</phone>
    <email>cycdc2011@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Li Li</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shanxi Centers for Disease Control and Prevention</name>
      <address>
        <city>Yuncheng</city>
        <state>Shanxi</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li</last_name>
    </contact>
    <investigator>
      <last_name>Guohua Li</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 28, 2013</study_first_submitted>
  <study_first_submitted_qc>May 28, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 31, 2013</study_first_posted>
  <last_update_submitted>June 25, 2013</last_update_submitted>
  <last_update_submitted_qc>June 25, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 26, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chickenpox</mesh_term>
    <mesh_term>Herpes Zoster</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

